NewslettersMesenchymal Cell News US FDA Approves QBiotics Investigational New Drug Application to Initiate Tigilanol Tiglate Soft Tissue Sarcoma Phase II Trial By Bob - July 26, 2022 0 QBiotics Group Limited has been granted approval of its Investigational New Drug application by the US FDA for lead oncology molecule, tigilanol tiglate. [QBiotics Group Limited] Press Release